Retatrutide: What Did Phase 1 and Phase 2 Find?

What matters most about retatrutide?

Retatrutide remains unapproved; current tests involve obesity and type 2 diabetes. This page tells you what happened in people, what caused harm, and which facts are missing. The drug acts like three hormones, the chemical messengers that your glands and organs release to guide hunger, blood sugar, and the way your body stores or burns fat. Studies call one of them GLP-1.

In one 48-week study, the highest-dose group lost an average of 24.2% of its body weight. Your result could differ because study staff watched those people closely. Phase 3 is the last large round of testing before a possible review, and those studies aren't finished. Retatrutide remains investigational and has no FDA-approved use.

Published study papers supply these facts. No clinic, seller, or care service backs this site. You can read separate personal accounts on the effects page.

People posting those accounts describe both welcome and unwanted changes. The posts didn't come from a study comparing retatrutide with a placebo. Study staff haven't checked the claims or the bottles. One person's story can't tell how your body would respond.

What does retatrutide do inside the body?

Retatrutide is a man-made chain of 39-amino-acid parts, the small pieces that form a protein. Its shape lets it act like three hormones at once. Those hormones affect blood sugar, hunger, and how your body stores or burns fat.

Your gut releases GLP-1 after food; this hormone helps your brain notice fullness and your body release insulin. A second gut hormone also helps with insulin and fat storage. Glucagon, a hormone made by the pancreas, frees stored fuel when your body needs it. Each hormone works through a receptor, which is a docking place on a cell.

Early animal work compared this three-hormone drug with drugs with the effects of one or two hormones ^[7]. Later lab pictures showed retatrutide gripping all three cell receptors ^[3]. GLP-1 uses one of them. The drug held each receptor with a different strength. That may change the strength of each hormone effect, but protein work can't forecast your response.

Your hunger may ease, your blood sugar may fall, and your body may burn more stored fuel. Retatrutide mechanism of action follows those steps. Retatrutide research keeps human findings apart from animal and cell work. Your age and health can change both the help and the harm.

What were the main retatrutide results?

The main Phase 2 weight study appeared in 2023 and followed 338 adults with obesity. Their height-and-weight number was 30 or more, which marks obesity on that scale. Each person in the test got a weekly shot of 1, 4, 8, or 12 mg, or a placebo, for 48 weeks. A placebo looks like the treatment but has no active drug.

Average weight at the highest dose fell 24.2%. The placebo group lost 2.1%, leaving a gap of about 22 percentage points ^[1]. Higher amounts brought more nausea and bowel trouble. The pulse increase peaked near week 24, but this summary doesn't give its size ^[1]. This line alone can't show how serious that change was.

The diabetes study followed 281 adults with type 2 diabetes. Study staff raised the drug amount in steps from 0.5 to 12 mg. At 24 weeks, the 12 mg group had a 2.02% drop in a blood test showing usual sugar levels.

That blood test covers the past few months. The placebo group changed 0.01%, while weight fell 16.94% against 3.00% by week 36 ^[2]. There were no deaths or dangerous low-sugar spells in that study.

A smaller study involved people with a fatty liver illness linked to poor use of food as fuel. With 12 mg, liver fat fell 82.4% at 24 weeks. Also, 86% of that group fell below 5% liver fat ^[5]. Nature Medicine published the paper, but this small group can't tell how your liver would respond. A doctor who knows your health can set those averages beside your health.

Is retatrutide FDA approved yet?

Retatrutide remains investigational, with no FDA-approved form. Eli Lilly is running large Phase 3 studies called TRIUMPH. This is the final large round of human testing before officials may review a drug. There is no approved label telling your doctor how to use retatrutide.

Semaglutide and tirzepatide are related drugs that act like one or two gut hormones. Both have approval for set uses, checked supplies, and years of reports from wider use. Retatrutide has none of those safeguards. A bottle sold under that name may contain a different drug or strength.

The Phase 3 work includes TRIUMPH-1, -2, and -3. Other studies are checking heart and kidney safety. No one has set a firm date for a ruling. Retatrutide cannot be prescribed through telehealth while it remains investigational. For you, no approval means no checked product and no official care guide.

Where is retatrutide available now?

Retatrutide has no approved product available for routine care. Neither a telehealth visit nor a compounding prescription provides access to retatrutide. The tested drug is available only to eligible participants in clinical studies. There, the study team knows what each shot holds and watches every person.

Online shops also list bottles carrying a research-only label. In 2025, more than 50 FDA warnings went to sellers under federal food and drug law. Such bottles may have the wrong strength, damaged protein pieces, or another substance. Tests of similar bottles from other sellers have found each of those problems.

When will retatrutide be available as an approved drug? The answer depends on the Phase 3 results and a full review by health officials. No date for routine prescription availability is established. Any firm date is still a guess. A seller's certainty isn't proof that a bottle is safe.